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Abstract
Background Perivascular spaces can become detectable on magnetic resonance imaging (MRI) upon enlargement, referred 
to as enlarged perivascular spaces (EPVS) or Virchow-Robin spaces. EPVS have been linked to small vessel disease. Some 
studies have also indicated an association of EPVS to neuroinflammation and/or neurodegeneration. However, there is 
conflicting evidence with regards to their potential as a clinically relevant imaging biomarker in multiple sclerosis (MS).
Methods To perform a systematic review and meta-analysis of EPVS as visualized by MRI in MS. Nine out of 299 original 
studies addressing EPVS in humans using MRI were eligible for the systematic review and meta-analysis including a total 
of 457 MS patients and 352 control subjects.
Results In MS, EPVS have been associated with cognitive decline, contrast-enhancing MRI lesions, and brain atrophy. Yet, 
these associations were not consistent between studies. The meta-analysis revealed that MS patients have greater EPVS 
prevalence (odds ratio = 4.61, 95% CI = [1.84; 11.60], p = 0.001) as well as higher EPVS counts (standardized mean dif-
ference [SMD] = 0.46, 95% CI = [0.26; 0.67], p < 0.001) and larger volumes (SMD = 0.88, 95% CI = [0.19; 1.56], p = 0.01) 
compared to controls.
Conclusions Available literature suggests a higher EPVS burden in MS patients compared to controls. The association of 
EPVS to neuroinflammatory or -degenerative pathology in MS remains inconsistent. Thus, there is currently insufficient 
evidence supporting EPVS as diagnostic and/or prognostic marker in MS. In order to benefit future comparisons of studies, 
we propose recommendations on EPVS assessment standardization in MS. PROSPERO No: CRD42019133946.
Keywords Multiple sclerosis · Enlarged perivascular spaces · Systematic review · Meta-analysis · Magnetic resonance 
imaging · Biomarker
Introduction
Perivascular spaces surround blood vessel walls penetrat-
ing the brain parenchyma through the subarachnoid space 
and are mostly microscopical [43]. Perivascular spaces 
seem to play a potential role in the pathogenesis of neuro-
inflammatory diseases such as multiple sclerosis (MS), as 
supported by several lines of evidence: perivascular spaces 
are inhabited by MHC-II presenting macrophages and den-
dritic cells, as well as patrolling lymphocytes (including T 
cells) [14, 42]. Perivascular spaces have also been proposed 
as lymphatic efflux pathways from the brain [29], which is 
devoid of lymphatic vessels and has long been considered as 
“immune-privileged” organ [13]. Thus, perivascular spaces 
seem to represent a hot spot of immune cell interaction. 
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This has also been corroborated using in vivo microscopy 
in rodents upon initiation of neuroinflammation [4].
Upon a certain size, perivascular spaces can become 
detectable on magnetic resonance imaging (MRI), referred 
to as enlarged perivascular spaces (EPVS) or Virchow-Robin 
spaces [45]. EPVS are detectable on T2- and on T1-weighted 
MR images as cerebrospinal fluid (CSF)-isointense struc-
tures which are correlated with perforating brain vessels 
[5]. Of note, the exact anatomical compartment of EPVS 
including their relation to the vascular tree is controversial 
[12, 16, 32].
Although few scattered perivascular spaces are an almost 
ubiquitous imaging finding, an increase in EPVS burden has 
been associated to small vessel disease [3], which increases 
the risk for stroke, dementia [10], and other neurodegenera-
tive diseases [19, 39].
Accumulating evidence also suggests an association of 
EPVS to MS. However, as of yet there is no established role 
for EPVS as imaging biomarker in MS, since existing data 
is partly contradictory. Thus, some studies describe an asso-
ciation of EPVS with certain disease characteristics, others 
contradict these findings. Furthermore, studies show con-
siderable methodological differences. The aim of this study 
was to perform a systematic review and meta-analysis on the 
current literature on EPVS in MS, including their correlation 
to other imaging features and clinical characteristics.
Methods
We registered the study protocol in the International pro-
spective register of systematic reviews (PROSPERO, 
CRD42019133946, https ://www.crd.york.ac.uk/PROSP 
ERO/) and used the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis (PRISMA) Guidelines for 
reporting [34].
Search strategy
We searched for original observational studies published in 
full up to 26th of April 2020 in PubMed, Web of Science, 
and Ovid EMBASE using search terms for EPVS in conjunc-
tion with MS/neuroinflammation. See Supplementary Meth-
ods for the exact search string in each of these data bases.
Inclusion and exclusion criteria
We included publications that reported on any outcome related 
to EPVS, as assessed by MRI, and their associations with 
any disease feature of MS in humans. Case reports were also 
included to the systematic review. Exclusions: animal studies, 
non-English articles, reviews and papers which did not include 
quantitative data or papers which reported on quantitative data 
that were previously reported.
Study selection and data extraction
Titles and abstracts of studies were screened for their relevance 
in the web-based application Rayyan by two reviewers fol-
lowed by full-text screening [36]. For more detailed informa-
tion on data extraction, see supplementary material.
Quality assessment
The quality of each study was assessed against pre-defined cri-
teria by two reviewers (Supplementary Tables 1 and 2) using 
QUADAS-2, the revised version of QUADAS [46].
Data synthesis and analysis
For the meta-analysis, we used summary-level data only. As 
primary outcome, we assessed differences in EPVS burden 
between MS patients and controls. Since absolute differences 
in EPVS were assessed using different methods across stud-
ies, standardized mean differences (SMDs) with 95% confi-
dence interval (CI) were reported as measure of association for 
continuous outcome measures. We also extracted odds ratios 
(ORs) with 95% CI as relative measure of association for those 
studies comparing the existence of EPVS in MS patients ver-
sus controls. Analyses comparing the burden of EPVS in MS 
patients vs. controls were stratified by unit of measurement 
and brain region of EPVS assessment. Secondary outcomes 
of our meta-analysis included disease-specific associations 
of EPVS with clinical and neuroimaging biomarkers in MS 
patients. These associations were assessed using either mean 
differences or ORs as described above.
For each association of interest, between-study heterogene-
ity was assessed using the I2 statistics [22]. SMDs and ORs 
were pooled using random effects models. A two-tailed p 
value < 0.05 was considered statistically significant. All analy-
ses were carried out using Review Manager Software Version 
5.3 (Cochrane, Oxford).
Publication bias
Publication bias was not assessed since only nine studies were 
included in the meta-analysis (in the pre-defined protocol, ten 
studies had been defined as threshold for assessing publica-
tion bias).
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Results
Eligible publications
In total, 299 original publications were retrieved from our 
comprehensive data base search. After abstract and title 
screening, 46 studies were eligible for full-text search. After 
screening the full text of these studies, nine articles were 
included for quantitative synthesis (Fig. 1).
General study characteristics
When pooled, the studies contained a total of 457 MS 
patients and 352 control subjects. All clinical MS subtypes 
were represented in the studies (relapsing–remitting MS 
[RRMS], secondary progressive MS [SPMS], primary pro-
gressive MS [PPMS]). One study also included 21 patients 
with clinically isolated syndrome (CIS) [17]. Table 1 sum-
marizes the included studies assessing the role of EPVS in 
MS using MRI.
Two out of nine studies had a prospective design with 
a follow-up of up to ten years [7, 48]. Increasing age is a 
known contributor to the presence of EPVS in the general 
population [19] and previous studies have shown variations 
in EPVS between men and women [26]. All studies were at 
least matched on age and sex. EPVS have also been associ-
ated with cerebrocardiovascular disease [19, 39]. One study 
reported that no patient had cardiovascular risk factors [17]. 
Table 1 summarizes patient cohorts and methodology of the 
included studies.
Methodological assessment of perivascular spaces 
using magnetic resonance imaging
One major difference between the studies was the difference 
in the static magnetic field strength of the used MR imaging 
system: Four studies used 1.5 T (T); one study used 2 T; 
three studies used 3 T; and one study used 7 T.
All studies defined EPVS as cerebrospinal fluid (CSF)-
isointense punctuate structures on T1- and/or T2-weigted 
images, as well as their conforming path along penetrat-
ing arteries, e.g. in the semioval center or along the len-
ticulostriate arteries. All except one study assessed EPVS 
on T1- and T2-weighted images, the remaining study only 
used T2-weighted images to assess EPVS [7]. Acquired MR 
sequences per study are listed in Table 1. Most studies fur-
ther report that EPVS can readily be discriminated from MS 
lesions or small lacunes by their hypointense appearance on 
fluid-attenuated inversion recovery [FLAIR] T2-weighted 
images, in contrast to the hyperintense appearance of MS 
lesions/lacunes on FLAIR T2-weighted images (Fig. 2). One 
study used phase-sensitive inversion recovery (PSIR) ena-
bling enhanced T1 contrast [31], which may have resulted 
in higher sensitivity to detect EPVS [17].
In seven out of nine studies, two or more independent 
raters quantified EPVS. Interrater agreement was reported by 
three studies and ranged between 90 and 100% [1, 17, 48]. In 
two studies, only a single rater quantified EPVS.
While there was a high level of agreement on how to define 
EPVS, there were considerable differences in how the studies 
measured EPVS: all studies assessed EPVS count (manually 
using software packages such as MIPAV or ITK-SNAP or 
semi-automatic using threshold-based post-processing pipe-
lines [48]) and three studies also used semi-quantitative rating 
scales for EPVS counts [1, 2, 7], either according to Heier 
et al. [21] or Potter et al. [38]. In addition to EPVS counts, 
four studies measured EPVS volume [8, 9, 17, 48]; four studies 
Fig. 1  Flow chart depicting the 
study selection process
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categorized EPVS as dilated or non-dilated (using a threshold 
of 2 mm or 2 mm3) [2, 8, 15, 17]; three studies measured the 
EPVS area on representative axial slices [8, 9, 25]; two stud-
ies either excluded EPVS > 2 mm [1] or < 2 mm [17]; and one 
study assessed the shape of EPVS (round, oval or curvilinear) 
[15].
The anatomical location of EPVS assessment also varied 
across studies. Three characteristic locations for EPVS assess-
ment have been proposed—along the lenticulostriate arteries, 
semioval center and brain stem [28]. Four studies assessed 
EPVS in these locations [2, 7, 8, 15]; one study further sub-
categorized these three locations into a total of five different 
locations [25]. Three studies quantified EPVS in the whole 
brain without reporting area-specific-counts [9, 17, 48] and 
one study only assessed EPVS in the semioval center [1].
Differences in enlarged perivascular spaces 
comparing MS patients to controls
We retrieved ORs for whole brain EPVS from six studies 
comparing MS patients to controls (including a total of 360 
MS patients and 232 controls). Data from two studies could 
not be included in our meta-analysis due to non-estimatable 
ORs [7, 25]. According to our meta-analysis, whole brain 
EPVS were more common in MS patients than in controls 
(OR 4.61, 95% CI [1.84; 11.60], p = 0.001, Fig. 3a). There 
was, however, substantial heterogeneity between stud-
ies assessing whole brain EPVS (I2 = 72%) [23]. In strati-
fied analyses by brain region a similar trend of association 
between EPVS and MS was found for studies assessing 
EPVS in the brain stem (p = 0.054, Fig. 3d), whereas no 
strong evidence of an association was observed in studies 
assessing EPVS in the semioval center (Fig. 3b) and basal 
ganglia (Fig. 3c). Also, between-study heterogeneity was 
substantial among studies assessing EPVS in the semioval 
center.
A total of six studies assessed absolute differences in 
EPVS outcome measures between MS patients and controls. 
Results of these analyses, stratified by unit of measurement 
(i.e. area, volume, count) are summarized in Fig. 4. Overall, 
a similar pattern of association was observed for each unit 
of measurement, with SMDs not being different in these 
analyses, even though the SMD for EPVS area was only 
borderline significant. I.e. compared to controls, MS patients 
had a larger EPVS volume (SMD = 0.88, 95% CI = [0.19; 
1.56]), area (SMD = 0.79, 95% CI = [− 0.03; 1.60]) and 
count (SMD = 0.46, 95% CI = [0.26; 0.67]), with the latter 
being consistent with the whole brain ORs observed.
Studies examining associations of EPVS with MRI brain 
volume or lesion measures did not yield sufficient numbers 
for meta-analysis, and these results are therefore summa-
rized individually below.
Associations of enlarged perivascular spaces 
with clinical and imaging determinants in MS 
patients
Age
Two studies investigated the contribution of ageing to EPVS 
in MS: one study found an increase in EPVS counts in MS 
patients with increasing age [25] whereas the other only 
found such an association in the control group [48].
Sex
One study reported that male sex is a positive contributor to 
EPVS numbers in the semioval center in MS patients [15]. 
No such difference was observed in the control group.
Clinical outcomes
Five studies assessed the association between EPVS and 
physical disability, measured either by expanded disability 
Fig. 2  Enlarged perivascular spaces (EPVS) are readily detectable on 
T1- and fluid-attenuated inversion recovery (FLAIR) T2-weighted 
(T1w, T2w) magnetic resonance imaging (MRI) as cerebrospinal 
fluid-isointense punctuate structures (red arrowheads) in the semioval 
center (a and b) and in the basal ganglia (c and d). In contrast, mul-
tiple sclerosis lesions appear hyperintense on FLAIR T2-weighted 
images (blue arrowhead in b)
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status scale (EDSS) [9, 17, 25, 48] or general neurologi-
cal disability [1]—none of these found an association of 
EPVS with physical disability. One study found a positive 
trend (p = 0.051) between EPVS number and fatigue [8], 
as measured by the fatigue severity scale (FSS) [27]. This 
analysis was, however, not adjusted for age, sex or MS dis-
ease features. Another study found a positive correlation 
between dilated EPVS (> 2 mm) and cognitive decline in 
MS [17], again without adjustment for potential confound-
ing factors.
Fig. 3  Pooled analyses of studies comparing the odds of enlarged 
perivascular spaces (EPVS) in multiple sclerosis (MS patients ver-
sus controls. Odds ratios (ORs) for EPVS comparing MS patients to 
controls were extracted and pooled using the random effects Mantel–
Haenszel method. Pooled analyses were stratified by brain region of 
EPVS assessment: a whole brain, b semioval center, c basal ganglia 
and d brain stem. Of note, odds ratios were not estimatable in two 
studies assessing whole brain EPVS as EPVS in these studies were 
detected in all MS patients and controls [7, 25]. CI confidence inter-
val, df degrees of freedom, M–H Mantel–Haenszel
 Journal of Neurology
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Imaging outcomes
Studies assessing the association of EPVS with gadolinium 
(Gd) contrast-enhancing MRI lesions are conflicting. The 
first study investigating the association with Gd-enhancing 
MRI lesions in MS patients was by Achiron and Faibel [1]. 
In their retrospective study consisting of 71 newly diagnosed 
MS patients, no association between EPVS counts and Gd-
enhancing lesions was observed. Another retrospective study 
including 43 MS patients corroborated these findings show-
ing no association between EPVS count and volume with 
Gd-enhancing lesions [17]. In contrast, however, a prospec-
tive study including 45 MS patients, with longitudinal fol-
low-up of 18 MS patients for 12 months found a larger EPVS 
volume and a higher EPVS counts accompanying the occur-
rence of new Gd-enhancing lesions [48]. Yet, four studies 
consistently report the absence of an association between 
EPVS counts/volumes and T2 lesions [17, 25], two of which 
used a prospective design [7, 48].
The association of EPVS with brain atrophy has been 
assessed in six out of nine studies. Five out of six studies 
did not find an association between EPVS and brain vol-
umetry [7–9, 17, 48]. In all these studies, brain volumes 
have been computed using the package SIENAX from the 
software FSL [24]. One study including 34 MS patients 
and 11 healthy controls did, however, detect an association 
between EPVS and supratentorial brain fraction as computed 
by the surface-based software FreeSurfer [18]. Notably, it 
is the only study employing supratentorial brain fraction 
as outcome. All other studies used whole brain parenchy-
mal fraction (BPF) [40], defined as the ratio of total brain 
parenchymal volume to the total intracranial volume, as the 
volumetric outcome. Moreover, the study by Kilsdonk and 
colleagues employed by far the highest MRI field strength 
(7 T) for the image acquisition and should thus have a very 
high EPVS detection sensitivity [25].
Fig. 4  Pooled analyses of studies assessing absolute differences in 
enlarged perivascular spaces (EPVS) comparing MS patients to con-
trols. Standardized mean differences were pooled using the random 
effects inverse-variance weighted method. Pooled analyses were 
stratified by unit of measurement: a EPVS area, b EPVS volume 
and c EPVS count. CI confidence interval, df degrees of freedom, IV 
inverse variance weighted
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Discussion
Main findings
In the nine studies included in our systematic review, we 
found considerable methodological differences between 
the studies hampering direct comparisons. In particular, 
this involved the MRI acquisition  (B0 field strength, imag-
ing protocol) and the methodology for EPVS quantification 
(location, EPVS count vs. volume vs. area). Nevertheless, 
our meta-analysis of these nine studies showed that overall 
EPVS are more frequently observed in MS patients than 
in control subjects. Moreover, MS patients display higher 
EPVS counts and larger EPVS volumes compared to control 
subjects.
Findings in the context of existing evidence
The role of EPVS in the MS pathophysiology remains poorly 
elucidated, in part due to inconsistent evidence. Of note, the 
exact anatomical definition of EPVS is also still a matter of 
debate [12]. This includes the content of EPVS: the scarce 
available evidence assessing the location of EPVS within the 
vascular tree indicates a correlation of EPVS with arterioles 
but not venules [5, 6]. However, this needs further elicuda-
tion. While EPVS are not specific for MS, our meta-analysis 
indicates that MS patients have higher EPVS volumes and 
counts compared to controls. The higher prevalence of EPVS 
in MS patients could hint towards disturbances in CNS fluid 
drainage and/or excess fluid leakage from the vasculature 
[35, 44]. However, it should be noted, that given the design 
of most of the studies included in this meta-analysis (i.e. 
mostly case control studies with retrospective data collec-
tion), the temporality of the association with EPVS presence 
and size could not reliably be addressed. Hence, it is unclear 
whether EPVS burden is a potential risk factor for MS, or 
merely represents an epiphenomenon of the disease process. 
From a clinical point of view, findings from this review sug-
gest a potential prognostic value of EPVS. However, since 
the independent predictive value and discriminatory power 
of EPVS has not been addressed in studies to date, this 
requires further investigation.
Notably, the only study reporting an association of EPVS 
counts to brain atrophy used the highest applied MRI field 
strength (7 T) and estimated supratentorial brain fraction 
via the software FreeSurfer [25] in contrast to studies which 
were not able to reproduce this association [7–9, 17, 48]. It 
has been shown previously that these mentioned factors can 
contribute considerably to differences in brain volumetry 
measures [20, 30]. From a pathophysiological viewpoint, 
the enlargement of perivascular spaces in MS (and other 
neurodegenerative disorders) could represent a local ex 
vacuo dilatation.
The association of EPVS to Gd-enhancing lesions is 
another matter of debate: one study with a prospective 
design demonstrated an association of EPVS volume and 
number to contrast-enhancing lesions thereby establishing 
EPVS as marker for ongoing neuroinflammation [48]. The 
authors speculated that local infiltration of immune cells as 
a perivascular cuff may lead to an enlargement of individual 
EPVS. Two studies did, however, not confirm these findings 
[1], only one associating EPVS volume (and not number) to 
contrast-enhancing lesions though [17].
The included studies used similar criteria to define EPVS, 
namely CSF-isointensity on T1- and T2-weighted images 
without mass effect. Nevertheless, the studies used a pleth-
ora of different EPVS characteristics and clinical/imaging 
outcome measures. EPVS outcome measures included semi-
quantitative rating scales [21, 38], counts, volumes, areas, 
diameters, or shapes. Some studies also only included EPVS 
above or below a certain diameter (2 mm as most commonly 
used cut-off). Similarly, a variety of different methods to 
assess imaging outcomes including brain atrophy or lesion 
measures were used by the studies (manual segmentation, 
semi-automated or fully automated approaches).
Limitations
Our study has a few limitations: (1) for most outcomes, only 
few studies could be included in our meta-analysis. This 
reflects the substantial methodological differences between 
the studies. (2) The presence of substantial heterogeneity 
between studies precluded the ability to explore sources of 
this heterogeneity using subgroup analyses. (3) For EPVS 
frequency between MS patients and control subjects, the 
OR was not estimatable in two studies in which EPVS were 
apparent in all patients and controls. Thus, the association of 
EPVS with MS might have been overestimated when pool-
ing ORs; however, results for differences in EPVS count 
(which is an equivalent outcome measure) were similar to 
those observed for ORs, corroborating the presence of a 
positive association between EPVS and MS. (4) EPVS have 
consistently been associated to cerebrovascular disease and 
neurodegeneration [19, 39]. Yet, only one of the included 
studies reported that patients had no cardiovascular risk 
factors [17]. Nevertheless, the mean age of the MS patient 
cohorts was presumably prior to relevant cerebrocardiovas-
cular and neurodegenerative disease onset.
In order to better define the role of EPVS as imaging bio-
marker, more studies with prospective design are required 
to minimize potential bias, which is apparent in some of the 
included studies. Standardization of EPVS measurement, not 
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least to emend comparability between studies, is another 
requirement.
Recommendations
To foster reliability and comparability of future studies, 
we recommend the following routine for EPVS imaging 
in MS: (1) the imaging protocol should include both a 
T1- and T2-weighted sequence, (2) at least 2 raters should 
independently assess EPVS, and (3) EPVS should not only 
be quantified in the whole brain, but also in different brain 
regions (semioval center, basal ganglia and brain stem). It 
is also noteworthy that several promising automated meth-
ods to quantify EPVS have been proposed whose future 
application will further increase reliability and compa-
rability of studies [11, 41]. Finally, assessing the shape 
of EPVS should also be considered since different EPVS 
characteristics might reflect different underlying patholo-
gies. Of note, the EPVS characteristics which define its 
role as imaging biomarker does not necessarily need to be 
similar for different diseases, e.g. between primary neu-
rodegenerative and neuroinflammatory disorders such as 
MS—in MS, measuring the diameter of EPVS might bet-
ter reflect a local accumulation of immune cells whereas 
increasing EPVS numbers might better reflect an ongoing 
widespread ex vacuo atrophy in cognitive decline.
Conclusions
This meta-analysis is the first to report at an aggregated 
level that the prevalence of EPVS is higher in MS patients, 
with higher EPVS burden compared to controls. This sup-
ports a potential role of EPVS in MS etiopathogenesis and 
its use as marker with prognostic potential. The role of 
EPVS as disease severity biomarker remains uncertain, 
however, not least to considerable methodological differ-
ences between studies as well as the limited number of 
studies addressing the role of EPVS as potential prognos-
ticator. Standardization of EPVS assessment will improve 
future comparability between studies. Finally, studies on 
correlation between MRI EPVS and underlying histopa-
thology could offer valuable clues on the role of EPVS 
in MS.
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